ALXN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017

NEW YORK, Jan. 3, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) securities between February 10, 2014 and November 9, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/alexion-pharmaceuticals. There is no cost or obligation to you.

According to the complaint, during the Class Period, Alexion made false and/or misleading statements and/or failed to disclose: (1) that the Company employed improper sales practices with respect to its product Soliris; (2) that the Company's revenues from Soliris sales were unlikely to be sustainable; and (3) that as a result of the above, Alexion's public statements were materially false and misleading at all relevant times.

On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. The Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this news was announced, shares of Alexion fell in value, causing investors harm.

If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/alexion-pharmaceuticals.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail:  vw@wongesq.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alxn-investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-alexion-pharmaceuticals-inc-and-a-lead-plaintiff-deadline-of-january-17-2017-300384722.html

SOURCE The Law Offices of Vincent Wong